Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data from Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer Oct 2, 2018
Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Aug 30, 2018
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer Aug 21, 2018
Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018 Jun 14, 2018
Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting Jun 4, 2018